Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Combined mechanical and pharmacological prophylaxis vs mechanical prophylaxis alone Adverse events · people undergoing bariatric surgery Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Neurological impairment (NIHSS) · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia All intracranial haemorrhage · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Target artery revascularisation status · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Time to revascularisation · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Adverse events · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
Endovascular treat ment plus medical treatment vs medical treatment alone Restenosis ‐ not measured · people with vertebral artery stenosis Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Endovascular treat ment plus medical treatment vs medical treatment alone Good functional outcome ‐ not measured · people with vertebral artery stenosis Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Suprasorb CNP system vs the ABThera system Participant health‐related quality of life · adults with an open abdomen after surgery who have not experienced trauma Negative pressure wound therapy for managing the open abdomen in non‐trauma patients (2022) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs the Bogota bag Proportion of participants with successful primary fascial closure of the abdomen · adults with an open abdomen after surgery who have not experienced trauma Negative pressure wound therapy for managing the open abdomen in non‐trauma patients (2022) · Cochrane | no estimate extracted | NR | No studies |
NPWT vs the Bogota bag Participant health‐related quality of life · adults with an open abdomen after surgery who have not experienced trauma Negative pressure wound therapy for managing the open abdomen in non‐trauma patients (2022) · Cochrane | no estimate extracted | NR | No studies |
Suprasorb CNP system vs the ABThera system Time to primary fascial closure of the abdomen · adults with an open abdomen after surgery who have not experienced trauma Negative pressure wound therapy for managing the open abdomen in non‐trauma patients (2022) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants vs no treatment Mortality related to COVID‐19 · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants vs no treatment Adverse events (minor bleeding) · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Higher‐dose anticoagulants vs lower‐dose anticoagulants Mortality related to COVID‐19 · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants vs no treatment Necessity for additional respiratory support · people hospitalised with COVID‐19 Anticoagulants for people hospitalised with COVID‐19: a rapid review (2022) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs probiotics Failure to induce clinical response at end of study · people with active UC Antibiotics for the induction and maintenance of remission in ulcerative colitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs 5‐ASA Failure to maintain clinical response at end of study · people with UC in remission Antibiotics for the induction and maintenance of remission in ulcerative colitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs no treatment Failure to induce clinical response at end of study · of active and inactive people with ulcerative colitis Antibiotics for the induction and maintenance of remission in ulcerative colitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics plus probiotics vs placebo or no intervention Failure to induce clinical response at end of study · people with active UC Antibiotics for the induction and maintenance of remission in ulcerative colitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs 5‐ASA Failure to induce clinical remission at end of study · people with active UC Antibiotics for the induction and maintenance of remission in ulcerative colitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Hypoxia‐inducible factor (HIF) stabilisers vs erythropoiesis‐stimulating agent (ESA) Life participation · people with CKD (including HD and PD) Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Hypoxia‐inducible factor (HIF) stabilisers vs placebo Fatigue · people with CKD (including HD and PD) Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Hypoxia‐inducible factor (HIF) stabilisers vs placebo Life participation · people with CKD (including HD and PD) Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Vitrectomy vs vitreous tap biopsy and antibiotic injection Mean change in best‐corrected visual acuity · people with endophthalmitis following intraocular surgery Early vitrectomy for exogenous endophthalmitis following surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
Vitrectomy vs vitreous tap biopsy and antibiotic injection Quality of life. · people with endophthalmitis following intraocular surgery Early vitrectomy for exogenous endophthalmitis following surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
Heated tobacco use vs snus use Smoking cessation – not measured · people who smoke Heated tobacco products for smoking cessation and reducing smoking prevalence (2022) · Cochrane | no estimate extracted | NR | No studies |
Heated tobacco use vs abstinence from tobacco Smoking cessation – not measured · people who smoke Heated tobacco products for smoking cessation and reducing smoking prevalence (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcome№ of participants(studies) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS/LABA · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR HD Triple vs. MD Triple · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD Triple · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcome№ of participants(studies) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcome№ of participants(studies) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcome№ of participants(studies) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outcome№ of participants(studies) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs prostaglandin analog Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs prostaglandin analog Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |